查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1461385

双特异性抗体市场：现况分析与预测（2023-2030）

Bispecific Antibody Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 136 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于核准数量的增加，双特异性抗体市场预计将稳定成长在 11.2% 左右。 例如，2022年10月，针对B细胞成熟抗原和CD3的双特异性抗体治疗药物Tecvayli将获得美国食品药物管理局的批准，作为治疗四线或以上治疗后持续存在的骨髓瘤的治疗方法。来自（FDA）。 在预测期内，有几个因素正在推动市场成长，例如增加对医疗保健产业的投资。 除此之外，双特异性抗体的加速上市增加了对有效治疗药物的需求，也稳定地推动了双特异性抗体市场的发展。

依药物类型划分，市场分为 blinatumomab、emicizumab、amivantamab 等。 由于产品批准增加，博纳吐单抗在 2022 年占据市场主导地位。 例如，2023年6月，Amgen向美国食品药物管理局提交了BLINCYTOR（blinatumomab）的补充生物製剂许可申请（sBLA），用于治疗患有CD19阳性B细胞前体急性淋巴细胞白血病的成人和儿童患者。 Blinatumomab 是一种新型免疫治疗药物，用于治疗某些类型的白血病。 Blinatumomab 是一种双特异性 T 细胞接合器 (BiTE) 抗体构建体。 Blinatumomab 透过同时结合 CD19（一种 B 细胞表面的蛋白质）和 CD3（一种 T 细胞表面的蛋白质）来发挥作用。 透过使 T 细胞与癌性 B 细胞紧密接触，blinatumomab 可以活化 T 细胞并靶向破坏它们。 因此，在药物类型中，blinatumomab在2022年占据了较大的市场占有率。

依适应症，市场分为癌症、血友病、黄斑部病变等。 由于血友病治疗的临床研究不断增加，预计血友病领域将在预测期内占据重要占有率。 例如，2021年7月，JW Pharmaceuticals在韩国A型血友病患者中评估了皮下注射Hemlibra的安全性、有效性和药物动力学，无论是否使用FVIII抑制剂。 双特异性抗体市场的血友病部分专注于开发治疗血友病的新治疗方法，血友病是一种以凝血因子缺乏或缺乏为特征的遗传性出血性疾病。 血友病传统上采用替代疗法治疗，即透过静脉注射缺乏凝血因子来预防或控制出血事件。 双特异性抗体有可能成为血友病患者的替代或补充疗法，解决其中一些尚未找到治疗方法的疾病。 因此，在预测期内，血友病在最终用户中将表现出更高的复合年增长率。

为了更瞭解市场，市场分为北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区）、亚洲太平洋地区（中国、日本、印度、其他亚太地区）和世界其他地区是根据其在世界其他地区的存在进行分析的。 由于癌症患者的快速增加、医疗保健成本的增加以及引入创新进步的举措和投资的增加，北美在 2022 年目前的情况下将主导市场。 例如，2023年5月，美国公司艾伯维宣布EPKINLYTM是第一个也是唯一一个获得美国食品药物管理局批准用于治疗復发或难治性（R/R）瀰漫性大B细胞淋巴瘤（ DLBCL）成年患者的T细胞疗法。 由于该地区病例的增加，政府机构启动了有关慢性病的认识计画。 因此，在这些地区中，北美将在2022年占据很大的市场占有率。

市场上营运的主要公司包括 Akeso Biopharma Co., Ltd.、Alexion Pharmaceuticals, Inc.、Amgen Inc.、Genmab A/S、Immunocore Ltd.、Janssen Global Services, LLC、Linton Pharm、Merck KGaA、Genentech, Inc.、Pfizer Inc.

目录

第一章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第二章研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对双特异性抗体市场的影响

第 6 章双特异性抗体市场收入，2020-2030

第七章药物类型市场分析

  • 博纳吐单抗
  • 艾美珠单抗
  • 阿米凡他单抗
  • 其他

第 8 章依指标进行市场分析

  • 癌症
    • 多发性骨髓瘤
    • 淋巴瘤
    • 白血病
    • 其他
  • 血友病
  • 黄斑部病变
  • 其他

第九章区域市场分析

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第10章双特异性抗体市场动态

  • 市场驱动因素
  • 市场课题
  • 影响分析

第11章双特异性抗体市场机会

第十二章双特异性抗体市场趋势

第十三章供需分析

  • 需求方分析
  • 供给面分析

第14章价值链分析

第15章比赛场景

  • 竞争状况
    • 波特五力分析

第十六章公司简介

  • Akeso Biopharma Co., Ltd.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Genmab A/S
  • Immunocore Ltd.
  • Janssen Global Services, LLC
  • Linton Pharm
  • Merck KGaA
  • Genentech, Inc.
  • Pfizer Inc.

第十七章免责声明

简介目录
Product Code: UMHE212690

Bispecific antibodies are engineered molecules that can bind to two different targets simultaneously. They're designed to redirect immune cells to target specific cells, such as cancer cells, enhancing the body's ability to fight diseases. These antibodies have gained attention in cancer therapy and other fields due to their potential to improve treatment efficacy and reduce side effects. A rising number of clinical trials and technological advancements to find effective treatments are leading to the market's growth. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the bispecific antibody market globally.

The Bispecific Antibody Market is expected to grow at a steady rate of around 11.2% owing to the rising drug approvals. For instance, in October 2022, Tecvayli, a bispecific antibody therapy targeting B-cell maturation antigen and CD3, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat myeloma that persisted after four or more lines of prior therapy. Several factors, including rising investments in healthcare departments, are driving the market's growth during the forecast period. Apart from this, the accelerated launch of bispecific antibodies has resulted in higher demand for effective treatment procedures which are also driving this market of bispecific antibodies at a steady rate.

Based on the drug type, the market is segmented into blinatumomab, emicizumab, amivantamab, and others. The blinatumomab segment dominated the market in the year 2022 owing to the rising product approvals. For instance, in June 2023, Amgen received the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA) for BLINCYTO(R) (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia. Blinatumomab is a novel immunotherapy drug used in the treatment of certain types of leukemia. Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct. It works by binding simultaneously to CD19, a protein found on the surface of B cells, and CD3, a protein found on the surface of T cells. By bringing T cells into proximity to cancerous B cells, blinatumomab activates the T cells, which then target and destroy the cancer cells. Thus, among the drug types, the blinatumomab segment held a significant market share in 2022.

Based on the indication, the market is categorized into cancer, hemophilia, macular degeneration, and others. The hemophilia segment is expected to hold a significant share of the market in the forecast period owing to the rising clinical studies for treating hemophilia. For instance, in July 2021, JW Pharmaceutical initiated a clinical trial to evaluate the safety, efficacy, and pharmacokinetics of FVIII Inhibitor titers of Hemlibra subcutaneous injection in Korean Hemophilia A patients with/without FVIII Inhibitors. The hemophilia segment in the bispecific antibody market focuses on developing novel therapeutic approaches to treat hemophilia, a genetic bleeding disorder characterized by deficiencies or defects in clotting factors. Hemophilia is traditionally treated with replacement therapy, where the deficient clotting factor is administered intravenously to prevent or control bleeding episodes. Bispecific antibodies offer a potential alternative or complementary therapy for hemophilia patients, addressing some of these unmet medical needs. Thus, the hemophilia category will witness a higher CAGR amongst end users during the forecast period.

For a better understanding, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the surge in cases of cancer, rising healthcare expenditure, and rising initiatives and investments in introducing innovative advancements. For instance, in May 2023, U.S-based AbbVie received U.S. Food and Drug Administration (FDA) approval for its EPKINLYTM as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Government organizations are initiating awareness programs for chronic diseases for the sake of the growing cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include Akeso Biopharma Co., Ltd.; Alexion Pharmaceuticals, Inc.; Amgen Inc.; Genmab A/S; Immunocore Ltd.; Janssen Global Services, LLC; Linton Pharm; Merck KGaA; Genentech, Inc.; Pfizer Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Bispecific Antibody Market
  • 2.2.Research Methodology of the Bispecific Antibody Market
  • 2.3.Respondent Profile

3.MARKET SYNOPSIS

4.EXECUTIVE SUMMARY

5.IMPACT OF COVID-19 ON THE BISPECIFIC ANTIBODY MARKET

6.BISPECIFIC ANTIBODY MARKET REVENUE (USD BN), 2020-2030F

7.MARKET INSIGHTS BY DRUG TYPE

  • 7.1.Blinatumomab
  • 7.2.Emicizumab
  • 7.3.Amivantamab
  • 7.4.Others

8.MARKET INSIGHTS BY INDICATION

  • 8.1.Cancer
    • 8.1.1.Multiple Myeloma
    • 8.1.2.Lymphoma
    • 8.1.3.Leukemia
    • 8.1.4.Others
  • 8.2.Hemophilia
  • 8.3.Macular Degeneration
  • 8.4.Others

9.MARKET INSIGHTS BY REGION

  • 9.1.North America
    • 9.1.1.U.S.
    • 9.1.2.Canada
    • 9.1.3.Rest of North America
  • 9.2.Europe
    • 9.2.1.Germany
    • 9.2.2.U.K.
    • 9.2.3.France
    • 9.2.4.Italy
    • 9.2.5.Spain
    • 9.2.6.Rest of Europe
  • 9.3.Asia-Pacific
    • 9.3.1.China
    • 9.3.2.Japan
    • 9.3.3.India
    • 9.3.4.Rest of Asia-Pacific
  • 9.4.Rest of World

10.BISPECIFIC ANTIBODY MARKET DYNAMICS

  • 10.1.Market Drivers
  • 10.2.Market Challenges
  • 10.3.Impact Analysis

11BISPECIFIC ANTIBODY MARKET OPPORTUNITIES

12BISPECIFIC ANTIBODY MARKET TRENDS

13DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1.Demand Side Analysis
  • 13.2.Supply Side Analysis

14.VALUE CHAIN ANALYSIS

15.COMPETITIVE SCENARIO

  • 15.1.Competitive Landscape
    • 15.1.1.Porters Fiver Forces Analysis

16.COMPANY PROFILED

  • 16.1.Akeso Biopharma Co., Ltd.
  • 16.2.Alexion Pharmaceuticals, Inc.
  • 16.3.Amgen Inc.
  • 16.4.Genmab A/S
  • 16.5.Immunocore Ltd.
  • 16.6.Janssen Global Services, LLC
  • 16.7.Linton Pharm
  • 16.8.Merck KGaA
  • 16.9.Genentech, Inc.
  • 16.10.Pfizer Inc.

17.DISCLAIMER